Schroeder W, Biesterfeld S, Zillessen S, Rath W
Department of Gynecology and Obstetrics, University Hospital of RWTH, Aachen, Germany.
Anticancer Res. 1997 Jul-Aug;17(4A):2799-802.
Epidermal growth factor receptor is considered to play an important role in the carcinogenesis and progression of breast cancer, but its clinical significance remains controversial mainly due to different methods and methodical problems. We determined EGF-R expression by an immunohistochemical assay on paraffin-embedded primary breast cancer tissue by means of the anti EGF-R mab E30 (Merck, FRG) and streptavidin-peroxidase technique. Material and clinical data were available from 111 patients with a mean follow-up time of 75.4 +/- 1.1 months (range 61-90 months). 21 (18.9%) of the breast cancer specimens showed positive staining for EGF-R 5 year-overall survival in patients with EGF-R negative tumors was 61.7% compared with 41.6% of patients with EGF-R positive breast carcinomas. No correlation was found between the expression of EGF-R and other prognostic factors except an inverse relationship with the expression of the estrogen receptor (p < 0.05). Whereas EGF-R expression demonstrated prognostic significance in univariate analysis, this could not be confirmed by multivariate analysis. Immunohistochemical determination of EGF-R represents a reliable and simple method to obtain more data about the biological behavior of malignant breast disease with increasing impact on therapeutic procedures.
表皮生长因子受体被认为在乳腺癌的发生和发展中起重要作用，但其临床意义仍存在争议，主要是由于方法不同及方法学问题。我们采用抗表皮生长因子受体单克隆抗体E30（德国默克公司）和链霉抗生物素蛋白-过氧化物酶技术，通过免疫组织化学方法检测石蜡包埋的原发性乳腺癌组织中表皮生长因子受体的表达。111例患者的资料和临床数据可供分析，平均随访时间为75.4±1.1个月（范围61 - 90个月）。21例（18.9%）乳腺癌标本表皮生长因子受体染色呈阳性。表皮生长因子受体阴性肿瘤患者的5年总生存率为61.7%，而表皮生长因子受体阳性乳腺癌患者为41.6%。除了与雌激素受体表达呈负相关（p<0.05）外，未发现表皮生长因子受体表达与其他预后因素之间存在相关性。虽然在单因素分析中表皮生长因子受体表达具有预后意义，但多因素分析未能证实这一点。免疫组织化学检测表皮生长因子受体是一种可靠且简单的方法，可获取更多关于恶性乳腺疾病生物学行为的数据，对治疗程序的影响日益增加。
